TNFRSF17 and Miyoshi myopathy: A case of irreversible B cell-maturation antigen(BCMA) loss was reported in a patient with MM who was enrolled in the KarMMa trial (NCT03361748) and progressed after anti-BCMA chimeric antigen receptor (CAR) T-cell therapy.